does the time to start first-line treatment influence the survival of favorable-risk patients with metastatic renal cell carcinoma? results of the metasurv-uroccr 79 study

Cyrielle Rolley; Philippe Barthelemy; Karim Bensalah; Francois-Xavier Nouhaud; Arnauld Villers; Franck Bruyere; Souhil Lebdai; Solene Ricard; Marine Gross-Goupil; Morgan Roupret; Jean-Christophe Bernhard; Pierre Bigot

doi:10.1016/j.clgc.2022.07.002

does the time to start first-line treatment influence the survival of favorable-risk patients with metastatic renal cell carcinoma? results of the metasurv-uroccr 79 study

Cyrielle Rolley
, Philippe Barthelemy
, Karim Bensalah
, Francois-Xavier Nouhaud
, Arnauld Villers
, Franck Bruyere
, Souhil Lebdai
, Solene Ricard
, Marine Gross-Goupil
, Morgan Roupret
, Jean-Christophe Bernhard
, Pierre Bigot

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	American English
Pages (from-to)	194-202
Number of pages	9
Journal	CLINICAL GENITOURINARY CANCER
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/j.clgc.2022.07.002
State	Published - 2022
Externally published	Yes

Funding Agency

Kuwait Foundation for the Advancement of Sciences

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clgc.2022.07.002

Cite this

Rolley, C., Barthelemy, P., Bensalah, K., Nouhaud, F.-X., Villers, A., Bruyere, F., Lebdai, S., Ricard, S., Gross-Goupil, M., Roupret, M., Bernhard, J.-C., & Bigot, P. (2022). does the time to start first-line treatment influence the survival of favorable-risk patients with metastatic renal cell carcinoma? results of the metasurv-uroccr 79 study. CLINICAL GENITOURINARY CANCER, 21(1), 194-202. https://doi.org/10.1016/j.clgc.2022.07.002

@article{5f40c1a07cf94b4fa9915dd162fda1b1,

title = "does the time to start first-line treatment influence the survival of favorable-risk patients with metastatic renal cell carcinoma? results of the metasurv-uroccr 79 study",

author = "Cyrielle Rolley and Philippe Barthelemy and Karim Bensalah and Francois-Xavier Nouhaud and Arnauld Villers and Franck Bruyere and Souhil Lebdai and Solene Ricard and Marine Gross-Goupil and Morgan Roupret and Jean-Christophe Bernhard and Pierre Bigot",

year = "2022",

doi = "10.1016/j.clgc.2022.07.002",

language = "American English",

volume = "21",

pages = "194--202",

journal = "CLINICAL GENITOURINARY CANCER",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "1",

}

Rolley, C, Barthelemy, P, Bensalah, K, Nouhaud, F-X, Villers, A, Bruyere, F, Lebdai, S, Ricard, S, Gross-Goupil, M, Roupret, M, Bernhard, J-C & Bigot, P 2022, 'does the time to start first-line treatment influence the survival of favorable-risk patients with metastatic renal cell carcinoma? results of the metasurv-uroccr 79 study', CLINICAL GENITOURINARY CANCER, vol. 21, no. 1, pp. 194-202. https://doi.org/10.1016/j.clgc.2022.07.002

does the time to start first-line treatment influence the survival of favorable-risk patients with metastatic renal cell carcinoma? results of the metasurv-uroccr 79 study. / Rolley, Cyrielle; Barthelemy, Philippe; Bensalah, Karim et al.
In: CLINICAL GENITOURINARY CANCER, Vol. 21, No. 1, 2022, p. 194-202.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - does the time to start first-line treatment influence the survival of favorable-risk patients with metastatic renal cell carcinoma? results of the metasurv-uroccr 79 study

AU - Rolley, Cyrielle

AU - Barthelemy, Philippe

AU - Bensalah, Karim

AU - Nouhaud, Francois-Xavier

AU - Villers, Arnauld

AU - Bruyere, Franck

AU - Lebdai, Souhil

AU - Ricard, Solene

AU - Gross-Goupil, Marine

AU - Roupret, Morgan

AU - Bernhard, Jean-Christophe

AU - Bigot, Pierre

PY - 2022

Y1 - 2022

U2 - 10.1016/j.clgc.2022.07.002

DO - 10.1016/j.clgc.2022.07.002

M3 - Article

SN - 1558-7673

VL - 21

SP - 194

EP - 202

JO - CLINICAL GENITOURINARY CANCER

JF - CLINICAL GENITOURINARY CANCER

IS - 1

ER -